Solid Organ Transplant Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Solid Organ Transplant clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 19 of 9 trials

Recruiting
Phase 4

Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.

Solid Organ Transplant
Murdoch Childrens Research Institute45 enrolled1 locationNCT06529536
Recruiting
Phase 2

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

LeiomyosarcomaSolid Organ Transplant ComplicationsLymphoproliferative Disorders+8 more
Pierre Fabre Medicament190 enrolled40 locationsNCT04554914
Recruiting
Phase 3

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Early Phase 1

Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT

Allogeneic Hematopoietic Stem Cell Transplantation RecipientAdenovirusCytomegalovirus+2 more
Sumithira Vasu20 enrolled2 locationsNCT03665675
Recruiting

Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

Solid Organ TransplantHematopoietic Cell TransplantRespiratory Viral Infection
Arkansas Children's Hospital Research Institute2,000 enrolled27 locationsNCT05550298
Recruiting
Not Applicable

iParent2Parent Program for Parents of Pediatric Solid Organ Transplant Recipients

Solid Organ Transplant
The Hospital for Sick Children55 enrolled1 locationNCT05968807
Recruiting
Phase 4

Letermovir for Secondary Prophylaxis in Solid Organ Transplant Recipients

NeutropeniaCytomegalovirus InfectionsInfection in Solid Organ Transplant Recipients+1 more
Tufts Medical Center25 enrolled1 locationNCT05626530
Recruiting

The Organ Transplant Recipient HPV and Skin Cancer Study

Cervical CancerSkin CancerHPV-Related Malignancy+4 more
Merete Haedersdal1,500 enrolled3 locationsNCT05284877
Recruiting

Microbiota Transplantation in Solid Organ Transplantation

Solid Organ Transplant Complications
The Second Hospital of Nanjing Medical University50 enrolled1 locationNCT06730451